Hangzhou Bio-Sincerity Pharma-Tech (301096.SZ) under its subsidiary Hangzhou Mipeng plans to invest 15 million yuan in a partnership enterprise to lay out strategic emerging industries such as biopharmaceuticals and hard technology.

Hangzhou Bio-Sincerity Pharma-Tech (301096.SZ) announced that the company intends to subscribe for shares in West Lake Innovation (Hangzhou) Science and Technology Achievements Transformation Entrepreneurship Investment Partnership Enterprise (Limited Partnership) through Hangzhou Mipeng Enterprise Management Partnership Enterprise (Limited Partnership) controlled by the company (referred to as "Hangzhou Mipeng"). Hangzhou Mipeng signed the "Partnership Agreement" on September 19, 2025. As a limited partner, Hangzhou Mipeng plans to subscribe for the corresponding contribution amount with its own funds of 15 million yuan. The investment target of the partnership enterprise is to carry out entrepreneurial investment activities in strategic emerging industries such as biomedicine and technology, focusing on investment opportunities in early-stage, small and medium-sized, and growth-stage enterprises.